198 related articles for article (PubMed ID: 8188616)
1. Glucosylceramide and glucosylsphingosine metabolism in cultured fibroblasts deficient in acid beta-glucosidase activity.
Sasagasako N; Kobayashi T; Yamaguchi Y; Shinnoh N; Goto I
J Biochem; 1994 Jan; 115(1):113-9. PubMed ID: 8188616
[TBL] [Abstract][Full Text] [Related]
2. The synthetic pathway for glucosylsphingosine in cultured fibroblasts.
Yamaguchi Y; Sasagasako N; Goto I; Kobayashi T
J Biochem; 1994 Sep; 116(3):704-10. PubMed ID: 7852294
[TBL] [Abstract][Full Text] [Related]
3. Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease.
Hamler R; Brignol N; Clark SW; Morrison S; Dungan LB; Chang HH; Khanna R; Frascella M; Valenzano KJ; Benjamin ER; Boyd RE
Anal Chem; 2017 Aug; 89(16):8288-8295. PubMed ID: 28686011
[TBL] [Abstract][Full Text] [Related]
4. Consequences of excessive glucosylsphingosine in glucocerebrosidase-deficient zebrafish.
Lelieveld LT; Gerhardt S; Maas S; Zwiers KC; de Wit C; Beijk EH; Ferraz MJ; Artola M; Meijer AH; Tudorache C; Salvatori D; Boot RG; Aerts JMFG
J Lipid Res; 2022 May; 63(5):100199. PubMed ID: 35315333
[TBL] [Abstract][Full Text] [Related]
5. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
[TBL] [Abstract][Full Text] [Related]
6. Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard.
Mirzaian M; Wisse P; Ferraz MJ; Gold H; Donker-Koopman WE; Verhoek M; Overkleeft HS; Boot RG; Kramer G; Dekker N; Aerts JM
Blood Cells Mol Dis; 2015 Apr; 54(4):307-14. PubMed ID: 25842368
[TBL] [Abstract][Full Text] [Related]
7. Role of β-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish.
Lelieveld LT; Mirzaian M; Kuo CL; Artola M; Ferraz MJ; Peter REA; Akiyama H; Greimel P; van den Berg RJBHN; Overkleeft HS; Boot RG; Meijer AH; Aerts JMFG
J Lipid Res; 2019 Nov; 60(11):1851-1867. PubMed ID: 31562193
[TBL] [Abstract][Full Text] [Related]
8. Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-D-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease.
Meivar-Levy I; Horowitz M; Futerman AH
Biochem J; 1994 Oct; 303 ( Pt 2)(Pt 2):377-82. PubMed ID: 7980395
[TBL] [Abstract][Full Text] [Related]
9. Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data.
Elleder M
J Inherit Metab Dis; 2006 Dec; 29(6):707-15. PubMed ID: 17080304
[TBL] [Abstract][Full Text] [Related]
10. In vitro accumulation of glucocerebroside in neuroblastoma cells: a model for study of Gaucher disease pathobiology.
Prence EM; Chaturvedi P; Newburg DS
J Neurosci Res; 1996 Feb; 43(3):365-71. PubMed ID: 8714525
[TBL] [Abstract][Full Text] [Related]
11. B cell lymphoma and myeloma in murine Gaucher's disease.
Pavlova EV; Wang SZ; Archer J; Dekker N; Aerts JM; Karlsson S; Cox TM
J Pathol; 2013 Sep; 231(1):88-97. PubMed ID: 23775597
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.
Sun Y; Liou B; Xu YH; Quinn B; Zhang W; Hamler R; Setchell KD; Grabowski GA
J Biol Chem; 2012 Feb; 287(6):4275-87. PubMed ID: 22167193
[TBL] [Abstract][Full Text] [Related]
13. Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology.
Sun Y; Florer J; Mayhew CN; Jia Z; Zhao Z; Xu K; Ran H; Liou B; Zhang W; Setchell KD; Gu J; Grabowski GA
PLoS One; 2015; 10(3):e0118771. PubMed ID: 25822147
[TBL] [Abstract][Full Text] [Related]
14. Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1.
Srikanth MP; Jones JW; Kane M; Awad O; Park TS; Zambidis ET; Feldman RA
Stem Cells Transl Med; 2021 Jul; 10(7):1081-1094. PubMed ID: 33656802
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.
Barnes S; Xu YH; Zhang W; Liou B; Setchell KD; Bao L; Grabowski GA; Sun Y
PLoS One; 2014; 9(12):e116023. PubMed ID: 25551612
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol glucosylation is catalyzed by transglucosylation reaction of β-glucosidase 1.
Akiyama H; Kobayashi S; Hirabayashi Y; Murakami-Murofushi K
Biochem Biophys Res Commun; 2013 Nov; 441(4):838-43. PubMed ID: 24211208
[TBL] [Abstract][Full Text] [Related]
17. Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes - A statistical insight.
Tylki-Szymańska A; Szymańska-Rożek P; Hasiński P; Ługowska A
Mol Genet Metab; 2018 Apr; 123(4):495-500. PubMed ID: 29530534
[TBL] [Abstract][Full Text] [Related]
18. Assay of β-glucosidase 2 (GBA2) activity using lithocholic acid β-3-O-glucoside substrate for cultured fibroblasts and glucosylceramide for brain tissue.
Harzer K; Yildiz Y; Beck-Wödl S
Biol Chem; 2019 May; 400(6):745-752. PubMed ID: 30864417
[TBL] [Abstract][Full Text] [Related]
19. Comparison of synthetic and natural glucosylceramides as substrate for glucosylceramidase assay.
Vaccaro AM; Kobayashi T; Suzuki K
Clin Chim Acta; 1982 Jan; 118(1):1-7. PubMed ID: 7053901
[TBL] [Abstract][Full Text] [Related]
20. Gaucher's disease.
Patel AL; Shaikh WA; Khobragade AK; Soni HG; Joshi AS; Sahasrabudhe GS; Chole PV
J Assoc Physicians India; 2009 May; 57():410-1. PubMed ID: 19634291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
